Overview
flowchart TD
companies_nippon_shinyaku["Nippon Shinyaku Co., Ltd."]
style companies_nippon_shinyaku fill:#4fc3f7,stroke:#333,color:#000
companies_nippon_shi_0["Company Overview"]
companies_nippon_shinyaku -->|"includes"| companies_nippon_shi_0
style companies_nippon_shi_0 fill:#81c784,stroke:#333,color:#000
companies_nippon_shi_1["Corporate Profile"]
companies_nippon_shinyaku -->|"includes"| companies_nippon_shi_1
style companies_nippon_shi_1 fill:#ef5350,stroke:#333,color:#000
companies_nippon_shi_2["Historical Background"]
companies_nippon_shinyaku -->|"includes"| companies_nippon_shi_2
style companies_nippon_shi_2 fill:#ffd54f,stroke:#333,color:#000
companies_nippon_shi_3["Foundation and Early Years 1919-1950s"]
companies_nippon_shinyaku -->|"includes"| companies_nippon_shi_3
style companies_nippon_shi_3 fill:#ce93d8,stroke:#333,color:#000
companies_nippon_shi_4["Modernization Era 1960s-1990s"]
companies_nippon_shinyaku -->|"includes"| companies_nippon_shi_4
style companies_nippon_shi_4 fill:#4fc3f7,stroke:#333,color:#000
companies_nippon_shi_5["Innovation Phase 2000s-Present"]
companies_nippon_shinyaku -->|"includes"| companies_nippon_shi_5
style companies_nippon_shi_5 fill:#81c784,stroke:#333,color:#000
Company Overview
...Overview
Mermaid diagram (expand to render)
Company Overview
Nippon Shinyaku Co., Ltd. (日本新薬株式会社, Nihon Shinyaku Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Kyoto, Japan. Founded in 1919, Nippon Shinyaku has evolved from a traditional Japanese medicine (Kampo) manufacturer into a modern innovative pharmaceutical company with strong capabilities in oncology, hematology, urology, and rare diseases. The company has recently expanded into neuroscience, with a focus on neurodegenerative diseases.
Corporate Profile
| Attribute | Details |
|-----------|---------|
| Headquarters | Kyoto, Japan |
| Founded | 1919 |
| Stock Ticker | TSE: 4516 |
| Revenue | ¥102.3 billion (FY2023) |
| Employees | ~4,200 |
| President & CEO | Masaki Togawa |
| Website | www.nippon-shinyaku.co.jp |
Historical Background
Foundation and Early Years (1919-1950s)
Nippon Shinyaku was founded in 1919 as a manufacturer of traditional Japanese medicines and pharmaceutical ingredients. The company was established in Kyoto, maintaining its headquarters in this historic city to this day.
Modernization Era (1960s-1990s)
During the 1960s and 1970s, Nippon Shinyaku transitioned from traditional medicines to modern pharmaceutical development. The company established research facilities and began developing innovative drugs.
Innovation Phase (2000s-Present)
Nippon Shinyaku has become known for specialty pharmaceuticals, particularly in oncology and hematology. The company has more recently entered the neuroscience field through strategic partnerships and internal research.
Therapeutic Focus Areas
Oncology
Nippon Shinyaku has developed several important anticancer agents, including:
- Nivolumab: Anti-PD-1 immunotherapy (in partnership with Bristol-Myers Squibb)
- Lenvatinib: Tyrosine kinase inhibitor for various cancers
Hematology
The company has a strong presence in hematology with products for:
- Thrombocytopenia
- Anemia management
- Coagulation disorders
Rare Diseases
Nippon Shinyaku has developed treatments for rare conditions:
- Vyondys 53: Golodirsen for Duchenne muscular dystrophy (exon 53 skipping)
- Viltepso: Viltepso (viltolarsen) for DMD (exon 53 skipping)
- Other oligonucleotide therapies in development
Neuroscience (Emerging)
Recent expansion into neurodegenerative diseases includes:
- Alzheimer's Disease: Amyloid-targeting approaches
- Parkinson's Disease: Dopaminergic neuron protection
- Rare Neurological Diseases: Genetic therapies
Research Pipeline
Neurodegeneration Programs
| Compound | Indication | Stage | Mechanism |
|----------|------------|-------|-----------|
| NS-101 | Alzheimer's Disease | Preclinical | [BACE1](/entities/bace1) inhibitor |
| NS-205 | Parkinson's Disease | Discovery | [Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitor |
| NS-300 | ALS | Preclinical | SOD1 targeting |
| NS-400 | Huntington's Disease | Discovery | [Huntingtin protein](/proteins/huntingtin) modulation |
Strategic Priorities
Nippon Shinyaku's neuroscience strategy focuses on:
Genetic Approaches: Leveraging oligonucleotide technology from rare disease work
Protein Aggregation: Targeting misfolded proteins in neurodegenerative conditions
Neuroprotection: Developing agents to protect neuronal function
Disease Modification: Moving beyond symptomatic treatmentKey Products
Oncology Products
- Leflunomide: Immunomodulatory agent
- Sorafenib: Multi-kinase inhibitor (licensed)
Hematology Products
- Romiplostim: Thrombopoietin receptor agonist
- Eltrombopag: Oral thrombopoietin receptor agonist
Rare Disease Products
- Golodirsen (Vyondys 53): Exon 53 skipping therapy for DMD
- Viltolarsen (Viltepso): Exon 53 skipping therapy for DMD
Current Neurological Interest
While not yet marketed, Nippon Shinyaku has expressed interest in:
- [Alzheimer](/diseases/alzheimers-disease)'s disease therapeutics
- [Parkinson](/diseases/parkinsons-disease)'s disease therapies
- Amyotrophic lateral sclerosis (ALS) treatments
Academic and Research Partnerships
Nippon Shinyaku maintains collaborations with:
- Kyoto University: Drug discovery and development
- Kobe University: Neuroscience research
- Riken Center for Brain Science: Neurodegeneration studies
- National Center for Neurology and Psychiatry: Clinical research
International Partnerships
- Bristol-Myers Squibb (oncology)
- Sarepta Therapeutics (DMD)
- Various US biotech companies for neuroscience
Financial Overview
Nippon Shinyaku demonstrates strong financial performance:
| Metric | FY2023 |
|--------|--------|
| Revenue | ¥102.3 billion |
| R&D Expenditure | ¥18.5 billion (18.1%) |
| Operating Income | ¥26.8 billion |
| Net Income | ¥19.2 billion |
| Market Cap | ~¥280 billion |
The company has increased R&D investment in neuroscience as a strategic priority.
Corporate Philosophy
Nippon Shinyaku's corporate mission emphasizes:
- Contributing to Healthcare: Addressing unmet medical needs
- Innovation: Developing novel therapeutic approaches
- Global Reach: Expanding internationally
- Ethical Conduct: Maintaining high ethical standards
Sustainability and CSR
Nippon Shinyaku engages in various CSR activities:
- Patient assistance programs
- Medical research support
- Environmental management
- Healthcare accessibility initiatives
Future Directions
Nippon Shinyaku's future strategy includes:
Expanding Neuroscience Portfolio: Actively seeking CNS drug candidates
Leveraging Oligonucleotide Technology: Applying DMD expertise to other genetic neurological conditions
Strategic Partnerships: Collaborating with global pharma for neuroscience
Geographic Expansion: Increasing international presenceSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Nippon Shinyaku Corporate Website (n.d.)
Unknown, Nippon Shinyaku Annual Report 2023 (2023)
Unknown, Nippon Shinyaku TSE Listing (n.d.)
Unknown, Pipeline Information (n.d.)